Research programme: antibody-drug conjugates - Heidelberg

Drug Profile

Research programme: antibody-drug conjugates - Heidelberg

Alternative Names: ADC - Heidelberg; Antibody-amanitin conjugates

Latest Information Update: 18 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma; University of Texas M. D. Anderson Cancer Center
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer

Most Recent Events

  • 18 Oct 2016 Research programme: antibody-drug conjugates - Heidelberg is available for licensing as of 13 Oct 2016. http://www.heidelberg-pharma.com/
  • 28 Jun 2016 Heidelberg Pharma has patent protection for synthesis of dihydroxyisoleucine in European Union
  • 02 Feb 2016 Heidelberg Pharma receives patent allowance for antibody drug conjugate in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top